Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

ECB. 2022; 11(6): 1-6


THE NOVEL POLYMERIC NANOCARRIER CONTAINING ASTRAGALIN DISPLAYS THE HEPATOPROTECTIVE EFFECT AGAINST CCl4-INDUCED LIVER INJURY IN VIVO

S. KALIDAS, P. GEETHA.




Abstract

A flavonoid with therapeutic qualities, astragalin is one of the least researched and has been utilized in Southeast Asian
traditional medicine. The protective effects of astragalin-loaded polymeric nanoparticles (AST-NPs) were formulated, optimized
using central composite factorial design (CCD), and evaluated Hepatoprotective activity on CCl4 -induced liver damage in
experimental rats. AST-NPs were prepared by the dialysis method.CCD was employed to study the influence of formulation factors,
polymer concentration, aqueous organic phase ratio, and process parameter stirring time on dependent physicochemical
characteristics, particle size, zeta potential, and percentage entrapment efficiency (%EE) of the drugs. In-vitro release studies,
stability tests, and an evaluation of the formulation's hepatoprotective activity were all conducted on the optimized formulation.
Fourier transmission infrared (FT-IR), differential scanning calorimetry (DSC), drug loading, entrapment effectiveness, particle
size, zeta potential, and in vitro investigations were used to characterize the produced NPs. There was no evidence of a drugpolymer interaction, according to FT-IR and DSC experiments. The improved NPs show stability. The zeta potential of -25 mV,
the %EE of 89%, and the mean PS of 118 nm of optimized PNPs all showed spherical and porous surfaces.

Key words: Astragalin, Central Composite Design, Encapsulation Efficacy, Hepatotoxicity, Particle Size, Polymer Nanoparticle.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.